Zou, Constance X.
Becker, Jessica E.
Phillips, Adam T.
Garritano, James M.
Krumholz, Harlan M.
Miller, Jennifer E.
Ross, Joseph S.
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (T35HL007649)
Article History
Received: 17 January 2018
Accepted: 3 October 2018
First Online: 23 October 2018
Ethics approval and consent to participate
: Not applicable
: Not applicable
: In the past 36 months, Ms. Zou received a fellowship through the Yale School of Medicine from the National Heart, Lung, and Blood Institute; Drs. Miller and Ross received research support through New York University from the Laura and John Arnold Foundation to support the Good Pharma Scorecard; Drs. Krumholz and Ross received research support through Yale University from Johnson & Johnson to develop methods of clinical trial data sharing, from Medtronic and the US Food and Drug Administration (FDA) to develop methods for postmarket surveillance of medical devices, and from the US Centers of Medicare and Medicaid Services (CMS) to develop and maintain performance measures that are used for public reporting; Dr. Krumholz also received compensation as a member of the Scientific Advisory Board for United Healthcare; and Dr. Ross also received research support through Yale University from the FDA to establish a Center for Excellence in Regulatory Science and Innovation (CERSI) at Yale University and the Mayo Clinic, from the Blue Cross Blue Shield Association to better understand medical technology evaluation, and from the Laura and John Arnold Foundation to support the Collaboration for Research Integrity and Transparency at Yale University. James Garritano is supported by the NIH Medical Scientist Training Program Training Grant T32GM007205. The remaining authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.